Innate Pharma: AZN should come back… and it may be better than expected

BUY, Fair Value EUR19 (+40%)
News published on October Wednesday 7, 2015
Share on

We reiterate our positive stance regarding the potential of IPH2201 as an add-on for the durvalumab franchise following a meeting with Pierre Dordion (IPH’s Chief Medical Officer). Our base-case scenario on the future development of IPH2201/durvalumab is not only confirmed… but may exceed our current expectations (either in solid tumors or in haematological malignancies).

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities